HPS Pharmacies wish to give notice that Pfizer is continuing to experience a supply interruption for Clopine® Suspension as follows:

Clopine® SuspensionClozapine 50 mg/mLARTG 142239  

This is a long-term supply issue. Normal supplies of Clopine® Suspension are expected to return in January 2025. This supply interruption does not affect Clopine® tablets.

Versacloz® Suspension is an internationally registered brand of clozapine oral suspension that has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.

Important points to note regarding Versacloz® Suspension:

  • Versacloz® Suspension appears less viscous than Clopine® Suspension and may have a slightly different taste;
  • Unlike Clopine® Suspension, Versacloz® Suspension does not need to be shaken 24 hours before the first use. It should still be shaken for 10 seconds prior to withdrawing each dose;
  • Patients should continue to be monitored on ClopineCentral™, noting the tradename of medicine being used; and
  • Versacloz® Suspension is subsidised on the Pharmaceutical Benefits Scheme (PBS).
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

Should you require further information regarding this matter, please contact Pfizer on 1800 675 229 or your pharmacist at HPS Pharmacies.

Subscribe Knowledge Centre Updates

Enter your details to receive Knowledge Centre updates